MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma

Author： Amato Robert J.   Stephenson Joe   Hotte Sebastien   Nemunaitis John   Bélanger Karl   Reid Gregory   Martell Robert E.  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.30, Iss.5, 2012-05, pp. : 415-421

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 4, Iss. 2, 2009-06 ,pp. : 146-156

Bentham Science Publishers

Access to resources Recommend Favorite

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

By                                                          

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 5-16

Spandidos Publications

Access to resources Recommend Favorite

Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma

By Procopio Giuseppe  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1267-1268

Humana Press, Inc

Access to resources Recommend Favorite

Transcriptional analysis of CXCR4, DNMT3A, DNMT3B and DNMT1 gene expression in primary advanced uterine cervical carcinoma

By                

International Journal of Oncology, Vol. 40, Iss. 3, 2012-01 ,pp. : 860-866

Spandidos Publications

Access to resources Recommend Favorite

Carfilzomib: a novel second-generation proteasome inhibitor

By Khan Meaghan L   Stewart A Keith  

Future Oncology, Vol. 7, Iss. 5, 2011-05 ,pp. : 607-612

Future Medicine

Access to resources Recommend Favorite